US SEC Trading Suspension Halt Orders — April 09, 2026

09-04-2026

Actelis Networks, Inc. (ASNS) was denied continued listing on Nasdaq Capital Market by the Nasdaq Hearings Panel due to failure to maintain a $1.00 minimum bid price for 30 consecutive business days, exacerbated by a prior 1-for-10 reverse stock split on November 18, 2025, leading to immediate delisting without a compliance period. Trading of ASNS common stock will be suspended on Nasdaq at the open of business on April 10, 2026, with the company planning to transition to OTC Markets (potentially OTCQB) while exploring options to relist on Nasdaq. The delisting is not expected to impact business operations, and the company will remain a reporting entity under the Securities Exchange Act.

• ·Nasdaq written notice received on February 4, 2026
• ·1-for-10 reverse stock split effected on November 18, 2025
• ·Common stock par value: $0.0001 per share

09-04-2026

On April 8, 2026, Gossamer Bio, Inc. received a notice from Nasdaq stating that its common stock (GOSS) failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days from February 24 to April 7, 2026, violating Nasdaq Listing Rule 5450(a)(1). The company has 180 calendar days until October 5, 2026, to regain compliance by achieving at least $1.00 closing bid price for ten consecutive business days, with no immediate delisting. Failure to comply could lead to transfer to Nasdaq Capital Market or delisting after potential appeal.

• ·Nasdaq Listing Rule referenced: 5450(a)(1) and 5810(c)(3)(A)
• ·Trading symbol: GOSS on Nasdaq Global Select Market
• ·Company address: 3115 Merryfield Row, Suite 120, San Diego, California, 92121
• ·Possible cure options include reverse stock split if transferring to Nasdaq Capital Market

09-04-2026

Kyntra Bio, Inc. (formerly associated with FibroGen) received a Nasdaq notice on April 2, 2026, for failing to meet the continued listing requirement of $50 million in total assets and total revenue for the most recently completed fiscal year under Listing Rule 5450(b)(3)(A), due to FibroGen International's revenue being classified as held for sale in discontinued operations for 2024 and 2025. The Company also does not satisfy alternative stockholders’ equity or market value standards. While there is no immediate delisting effect, it has 45 days until May 18, 2026, to submit a compliance plan, potentially earning a 180-day extension to September 29, 2026.

• ·Company may apply to transfer securities to the Nasdaq Capital Market.
• ·Nasdaq will evaluate compliance plan based on likelihood of success, past history, reasons for non-compliance, financial condition, and disclosures.

09-04-2026

Beyond Meat, Inc. received a Nasdaq deficiency notice on April 6, 2026, for failing to timely file its Form 10-K for the fiscal year ended December 31, 2025, violating Listing Rule 5250(c)(1), but filed the report on April 9, 2026, thereby regaining compliance and avoiding the need for a formal compliance plan by June 5, 2026. The notice had no immediate impact on the listing or trading of its common stock (BYND). The company also announced its 2026 virtual annual meeting of stockholders on May 20, 2026, at 8:00 a.m. Pacific Time, with a record date of March 24, 2026.

• ·Nasdaq Listing Rule violated: 5250(c)(1).
• ·Company address: 888 N. Douglas Street, Suite 100, El Segundo, California 90245.
• ·Securities registered: Common Stock, $0.0001 par value, trading symbol BYND.

09-04-2026

Newton Golf Company, Inc. received a deficiency notice from Nasdaq on April 6, 2026, for non-compliance with Listing Rule 5550(b)(1), failing to maintain the minimum stockholders’ equity of $2,500,000. The company has 45 days until May 21, 2026, to submit a compliance plan, potentially extendable to 180 days until October 3, 2026, if accepted, but there is no assurance of success. Trading of common stock (NWTG) continues uninterrupted for now, though delisting risk remains.

• ·Nasdaq Listing Rule 5550(b)(1) violated due to insufficient stockholders’ equity.
• ·Initial compliance plan submission deadline: May 21, 2026 (45 calendar days from notice).
• ·Potential extension: up to 180 calendar days from April 6, 2026 (until October 3, 2026).
• ·Common stock continues trading on Nasdaq Capital Market under symbol NWTG.